摘要
目的研究在特定2型糖尿病住院患者中应用达格列净联合胰岛素治疗的临床疗效及安全性。方法70例特定2型糖尿病住院患者,采用单双数分组法分为对照组和观察组,每组35例。对照组采用阿卡波糖联合胰岛素治疗,观察组采用达格列净联合胰岛素治疗。比较两组患者治疗前后血糖水平、胰岛素使用量及不良事件发生情况。结果治疗后,两组患者空腹血糖、餐后2 h血糖均较本组治疗前下降,且观察组下降程度大于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者胰岛素使用量均较本组治疗前减少,且观察组患者胰岛素使用量(0.21±0.14)U/(kg·d)少于对照组的(0.33±0.16)U/(kg·d),差异具有统计学意义(P<0.05)。两组患者不良事件发生率比较差异无统计学意义(P>0.05)。结论对特定2型糖尿病住院患者采用达格列净联合胰岛素治疗能够显著控制血糖水平,安全性较高。
Objective To study the clinical efficacy and safety of Dapagliflozin combined with insulin in inpatients with specific type 2 diabetes mellitus.Methods A total of 70 inpatients with specific type 2 diabetes mellitus were divided into control group and observation group according to odd-even grouping method,with 35 cases in each group.The control group was treated with acarbose and insulin,and the observation group was treated with Dapagliflozin and insulin.The blood glucose and dosage of insulin before and after treatment,and occurrence of adverse events were compared between the two groups.Results After treatment,the fasting blood glucose and 2 h postprandial blood glucose of the two groups were lower than those before treatment,and the observation group was lower than the control group.All the difference was statistically significant(P<0.05).After treatment,the dosage of insulin of the two groups were lower than those before treatment,and the dosage of insulin(0.21±0.14)U/(kg·d)of the observation group was less than(0.33±0.16)U/(kg·d)of the control group.All the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse events between the two groups(P>0.05).Conclusion Combination of Dapagliflozin and insulin can significantly control the blood glucose of inpatients with specific type 2 diabetes mellitus with high safety.
作者
于春梅
YU Chun-mei(Fuxin Diabetes Hospital,Fuxin 123000,China)
出处
《中国实用医药》
2021年第14期131-133,共3页
China Practical Medicine
关键词
达格列净
胰岛素
特定2型糖尿病
安全性
Dapagliflozin
Insulin
Specific type 2 diabetes mellitus
Safety
